Narrow your search

Library

KU Leuven (2)

Odisee (2)

Thomas More Kempen (2)

Thomas More Mechelen (2)

UCLL (2)

ULB (2)

ULiège (2)

VIVES (2)


Resource type

book (2)


Language

English (2)


Year
From To Submit

2015 (1)

2012 (1)

Listing 1 - 2 of 2
Sort by

Book
Medication-Related Osteonecrosis of the Jaws : Bisphosphonates, Denosumab, and New Agents
Author:
ISBN: 9783662437339 3662437325 9783662437322 3662437333 Year: 2015 Publisher: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs.  This textbook provides detailed, up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require extractions, implant insertions, and other dento-alveolar surgeries. This book will be of major interest for medical and dental students, dentists, and oral and maxillofacial surgeons as well as osteologists and oncologists.


Book
Bisphosphonates and osteonecrosis of the jaw : a multidisciplinary approach
Author:
ISBN: 8847020824 9786613453587 8847020832 1283453584 Year: 2012 Publisher: Milano ; New York : Springer-Verlag Italia,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Bisphosphonates are commonly prescribed to inhibit bone loss in patients with osteoporosis, as well as osteopenia, cancer, and Paget's disease of the bone. Recently, scientific literature has addressed a possible relationship between bisphosphonates and osteonecrosis of the jaw (ONJ). It is important to note that though the risks for developing ONJ are much higher for cancer patients on intravenous bisphosphonate therapy (used to reduce bone pain), the occurrence of ONJ also in patients treated with oral BF for osteoporosis has been also highlighted, though rarely. On the basis of the large use of BF, of their pharmacokinetics, of the systemic and local risk factors, physicians prescribing them and dental surgeons should be well informed on the various aspects of the problem. Aim of this volume is to offer an update on the current status of prevention, and on the current conservative and surgical treatments. The multidisciplinary approach will be very much appreciated by GP’s, the different specialists using bisphosphonates and by dental surgeons.

Listing 1 - 2 of 2
Sort by